Despite changes in antiarrhythmic drug (AAD) choice in patients with atrial fibrillation (AF), trends in AAD prescribing remain not investigated. We aimed to examine these changes using a nationwide Australian general practice data from 2009 to 2018. Over the 10 years, AAD prescribing in patients with AF decreased, which was mainly due to a reduction in the use of amiodarone, sotalol and digoxin. In contrast, the use of beta-blockers and flecainide increased.
History
Publication title
Internal Medicine Journal
Volume
51
Issue
10
Pagination
1732-1735
ISSN
1444-0903
Department/School
School of Pharmacy and Pharmacology
Publisher
Blackwell Publishing Asia
Place of publication
54 University St, P O Box 378, Carlton, Australia, Victoria, 3053